Literature DB >> 28887710

Increased mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: a 13-year retrospective study from one center.

Jekaterina Patrova1,2,3, Magnus Kjellman4,5, Hans Wahrenberg6,7, Henrik Falhammar6,4.   

Abstract

PURPOSE: To compare long-term outcomes in patients with adrenal incidentalomas (AIs) with the response to a 1 mg overnight dexamethasone suppression test (DST).
METHODS: Consecutive patients with "non-functional" AIs (n = 365) were examined. Patients with overt hormone excess, adrenocortical cancer and known malignancy had been excluded. Patients were classified to normal cortisol secretion group (n = 204, DST ≤ 50 nmol/l), possible autonomous cortisol secretion group (n = 128, DST 51-138 nmol/l) and autonomous cortisol secretion group (n = 33, DST ≥ 138 nmol/l).
RESULTS: Thirty-seven patients (10.1%) deceased during the follow-up period (5.2 ± 2.3 years): 16(7.8%) in the non-secreting group (time from diagnosis to death: 3.9 ± 2.9 years), 15 in the possible autonomous cortisol secretion group (11.7%, 3.2 ± 1.8 years) and 6 in the autonomous cortisol secretion group (18.2%, 2.3 ± 1.5 years), respectively (P = 0.019). Multivariate analysis only found significant association with age and the tumour size but if cortisol levels post-DST were analysed as a continuous variable it was significant as well. All deaths in autonomous cortisol secretion group were due to cancer not related to adrenal glands. Hypertension, cardiovascular disease and medications were more common in the possible and autonomous cortisol secretion group, especially in the former. More bilateral AIs and larger AI size were found in the two latter groups.
CONCLUSIONS: Patients with autonomous cortisol secretion had higher mortality than those with non-functioning AIs though cortisol levels post-DST as a continuous variable, age and tumour size were better predictor of mortality. Cardiovascular disease and osteoporosis medication seemed more prevalent in the possible and autonomous cortisol secretion groups, especially in the former.

Entities:  

Keywords:  Autonomous cortisol secretion; Cancer; Dexamethasone suppression test; Mortality; Prognosis; Subclinical Cushing’s syndrome

Mesh:

Substances:

Year:  2017        PMID: 28887710     DOI: 10.1007/s12020-017-1400-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  31 in total

1.  Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and biochemical features.

Authors:  R Rossi; L Tauchmanova; A Luciano; M Di Martino; C Battista; L Del Viscovo; V Nuzzo; G Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2000-04       Impact factor: 5.958

Review 2.  Subclinical hypercortisolism in adrenal incidentaloma.

Authors:  Miguel Debono; John Newell-Price
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2015-06       Impact factor: 3.243

3.  Development of overt Cushing's syndrome in patients with adrenal incidentaloma.

Authors:  Luisa Barzon; Francesco Fallo; Nicoletta Sonino; Marco Boscaro
Journal:  Eur J Endocrinol       Date:  2002-01       Impact factor: 6.664

4.  Vulnerability to stress-induced tumor growth increases with age in rats: role of glucocorticoids.

Authors:  R M Sapolsky; T M Donnelly
Journal:  Endocrinology       Date:  1985-08       Impact factor: 4.736

Review 5.  Cardiovascular disease in Cushing's syndrome: heart versus vasculature.

Authors:  Monica De Leo; Rosario Pivonello; Renata S Auriemma; Alessia Cozzolino; Pasquale Vitale; Chiara Simeoli; Maria Cristina De Martino; Gaetano Lombardi; Annamaria Colao
Journal:  Neuroendocrinology       Date:  2010-09-10       Impact factor: 4.914

Review 6.  NIH state-of-the-science statement on management of the clinically inapparent adrenal mass ("incidentaloma").

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Feb 4-6

7.  Depression, cortisol, and suppressed cell-mediated immunity in metastatic breast cancer.

Authors:  Sandra E Sephton; Firdaus S Dhabhar; Alex S Keuroghlian; Janine Giese-Davis; Bruce S McEwen; Alexei C Ionan; David Spiegel
Journal:  Brain Behav Immun       Date:  2009-07-28       Impact factor: 7.217

8.  Flattened cortisol rhythms in metastatic breast cancer patients.

Authors:  Heather C Abercrombie; Janine Giese-Davis; Sandra Sephton; Elissa S Epel; Julie M Turner-Cobb; David Spiegel
Journal:  Psychoneuroendocrinology       Date:  2004-09       Impact factor: 4.905

9.  "Nonfunctional" Adrenal Tumors and the Risk for Incident Diabetes and Cardiovascular Outcomes: A Cohort Study.

Authors:  Diana Lopez; Miguel Angel Luque-Fernandez; Amy Steele; Gail K Adler; Alexander Turchin; Anand Vaidya
Journal:  Ann Intern Med       Date:  2016-08-02       Impact factor: 25.391

10.  Limited value of long-term biochemical follow-up in patients with adrenal incidentalomas-a retrospective cohort study.

Authors:  Hannah Yeomans; Jan Calissendorff; Cristina Volpe; Henrik Falhammar; Buster Mannheimer
Journal:  BMC Endocr Disord       Date:  2015-02-27       Impact factor: 2.763

View more
  26 in total

1.  Prevalence of less severe hypercortisolism in fractured patients admitted in an outpatient clinic for metabolic bone diseases.

Authors:  F Pugliese; A S Salcuni; C Battista; V Carnevale; G Guglielmi; C Columbu; F Velluzzi; L Giovanelli; C Eller-Vainicher; A Scillitani; I Chiodini
Journal:  Endocrine       Date:  2021-01-23       Impact factor: 3.633

2.  Cardiovascular and metabolic risk factors in patients with subclinical Cushing.

Authors:  Luigi Petramala; Federica Olmati; Antonio Concistrè; Riccardo Russo; Martina Mezzadri; Maurizio Soldini; Giuseppe De Vincentis; Gino Iannucci; Giorgio De Toma; Claudio Letizia
Journal:  Endocrine       Date:  2020-04-16       Impact factor: 3.633

3.  The relationship between adrenal incidentalomas and mortality risk.

Authors:  Michio Taya; Viktoriya Paroder; Eran Bellin; Linda B Haramati
Journal:  Eur Radiol       Date:  2019-04-16       Impact factor: 5.315

4.  EFFECTIVENESS OF UNILATERAL ADRENALECTOMY IN BILATERAL ADRENAL INCIDENTALOMA PATIENTS WITH SUBCLINICAL HYPERCORTISOLEMIA.

Authors:  N Yilmaz; G Tazegul; R Sari; E Avsar; H Altunbas; M K Balci
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Oct-Dec       Impact factor: 1.104

5.  A machine learning approach to distinguishing between non-functioning and autonomous cortisol secreting adrenal incidentaloma on magnetic resonance imaging using texture analysis.

Authors:  Ferhat Can Piskin; Gamze Akkus; Sevinc Puren Yucel; Ilker Unal; Huseyin Tugsan Balli; Mehtap Evran Olgun; Murat Sert; Bekir Tamer Tetiker; Kairgeldy Aikimbaev
Journal:  Ir J Med Sci       Date:  2022-07-25       Impact factor: 2.089

6.  Adrenalectomy Improves Blood Pressure and Metabolic Control in Patients With Possible Autonomous Cortisol Secretion: Results of a RCT.

Authors:  Valentina Morelli; Sofia Frigerio; Carmen Aresta; Elena Passeri; Flavia Pugliese; Massimilano Copetti; Anna Maria Barbieri; Silvia Fustinoni; Elisa Polledri; Sabrina Corbetta; Maura Arosio; Alfredo Scillitani; Iacopo Chiodini
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

Review 7.  Cardiovascular risk and mortality in patients with active and treated hypercortisolism.

Authors:  Dingfeng Li; Omar M El Kawkgi; Andres F Henriquez; Irina Bancos
Journal:  Gland Surg       Date:  2020-02

Review 8.  Adrenal incidentaloma: cardiovascular and metabolic effects of mild cortisol excess.

Authors:  Alan Kelsall; Ahmed Iqbal; John Newell-Price
Journal:  Gland Surg       Date:  2020-02

Review 9.  Hidden hypercortisolism: a too frequently neglected clinical condition.

Authors:  L Giovanelli; C Aresta; V Favero; M Bonomi; B Cangiano; C Eller-Vainicher; G Grassi; V Morelli; F Pugliese; A Falchetti; L Gennari; A Scillitani; L Persani; I Chiodini
Journal:  J Endocrinol Invest       Date:  2021-01-04       Impact factor: 4.256

10.  Cardiometabolic Outcomes and Mortality in Patients with Adrenal Adenomas in a Population-based Setting.

Authors:  Catherine D Zhang; Dingfeng Li; Ravinder Jeet Kaur; Andreas Ebbehoj; Sumitabh Singh; Elizabeth J Atkinson; Sara J Achenbach; William F Young; Wiebke Arlt; Walter A Rocca; Irina Bancos
Journal:  J Clin Endocrinol Metab       Date:  2021-10-21       Impact factor: 6.134

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.